The efficacy of Advantix® to prevent transmission of Ehrlichia canis to dogs by Rhipicephalus sanguineus ticks

Parasite

and Frans Jongejan²  Dorothee Stanneck³  Herman Gerhardus Luus¹  Josephus Johannes Fourie¹ 

[1] ClinVet International (Pty) Ltd,PO Box 11186, Universitas, Bloemfontein 9321,South Africa;Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, Private Bag X04, Onderstepoort 0110,South Africa;Bayer Animal Health GmbH, BHC Business Group Animal Health, Clinical Development, Building 6700,51368 Leverkussen,Germany

关键词: Transmission;    Ehrlichiosis;    Rhipicephalus sanguineus;    Ehrlichia canis;    Permethrin;    Imidacloprid;   

Others  :  808483
DOI  :  doi:10.1051/parasite/2013037

 received in 2013-06-07, accepted in 2013-10-05,  发布年份 2013

【 摘 要 】

The capacity of a topical combination of imidacloprid and permethrin (Advantix®) to prevent transmission of Ehrlichia canis was studied in two groups of six dogs. One group served as controls, whereas the other group was treated. All dogs were exposed to E. canis-infected Rhipicephalus sanguineus ticks on Days 7, 14, 21 and Day 28 post acaricidal treatment. The adult R. sanguineus ticks were released into the individual kennels of the dogs to simulate natural tick exposure. In situ tick counts were conducted on Day 9, 16 and 23 and any remaining ticks were counted and removed on Day 30. The efficacy of the acaricidal treatment against R. sanguineus ranged between 96.1% and 98.9% at 48 h post-application and lasted up to 4 weeks. Four out of six control dogs became infected with E. canis, as demonstrated by the presence of specific E. canis antibodies and the detection by PCR of E. canis DNA in blood samples. These dogs became thrombocytopenic and displayed fever and were consecutively rescue-treated by doxycycline. None of the six treated dogs became infected with E. canis, as confirmed by the lack of specific antibodies and absence of E. canis DNA in blood samples. Advantix® prevented transmission of E. canis and provided protection against monocytic ehrlichiosis for 4 weeks post acaricidal treatment.

【 授权许可】

   
© J. J. Fourie et al., published by EDP Sciences, 2013

【 参考文献 】

• [1]Aguiar DM, Cavalcante GT, Pinter A, Gennari SM, Camargo LM, Labruna MB. 2007. Prevalence of Ehrlichia canis (Rickettsiales: Anaplasmataceae) in dogs and Rhipicephalus sanguineus (Acari: Ixodidae) ticks from Brazil. Journal of Medical Entomology, 44(1), 126–132. [PubMed]
• [2]Beugnet F, Marié JL. 2009. Emerging arthropod-borne diseases of companion animals in Europe. Veterinary Parasitology, 163, 298–305. [PubMed]
• [3]Blagburn BL, Spencer JA, Billeter SA, Drazenovich NL, Butler JM, Land TM, Dykstra CC, Stafford KC, Pough MB, Levy SA, Bledsoe DL. 2004. Use of imidacloprid-permethrin to prevent transmission of Anaplasma phagocytophilum from naturally infected Ixodes scapularis ticks to dogs. Veterinary Therapeutics, 5, 212–217.
• [4]Brown M, Hebert AA. 1997. Insect repellents: an overview. Journal of the American Academy of Dermatology, 36, 243–249. [PubMed]
• [5]Chomel B. 2011. Tick-borne infections in dogs – an emerging infectious threat. Veterinary Parasitology, 179, 294–301. [PubMed]
• [6]EMA. 2000. International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products Guideline 9: Good Clinical Practice. VICH GL9(GCP). European Medicines Agency, www.ema.europa.eu/docs/enGB/document library/Scientific guideline.
• [7]Epe C, Coati N, Stanneck D. 2003. Efficacy of the compound preparation imidacloprid 10%/permethrin 50% spot-on against ticks (I. ricinus, R. sanguineus) and fleas (Ct. felis) on dogs. Parasitology Research, 90, S122–S124. [PubMed]
• [8]Folz SD, Ash KA, Conder GA, Rector DL. 1986. Amitraz: a tick and flea repellent and tick detachment drug. Journal of Veterinary Pharmacology and Therapeutics, 9, 150–156. [PubMed]
• [9]Fourie JJ, Stanneck D, Jongejan F. 2013. Prevention of transmission of Babesia canis by Dermacentor reticulatus ticks to dogs treated with an imidacloprid/flumethrin collar. Veterinary Parasitology, 192, 273–278. [PubMed]
• [10]Fourie JJ, Ollagnier C, Beugnet F, Luus HG, Jongejan F. 2013. Prevention of transmission of Ehrlichia canis by Rhipicephalus sanguineus ticks to dogs treated with a combination of fipronil, amitraz and (S)-methoprene (CERTIFECT®). Veterinary Parasitology, 193, 223–228. [PubMed]
• [11]Fourie JJ, Stanneck D, Luus HG, Beugnet F, Wijnveld M, Jongejan F. 2013. Transmission of Ehrlichia canis by Rhipicephalus sanguineus ticks feeding on dogs and on artificial membranes. Veterinary Parasitology, 3 Aug 3. pii: S0304-4017(13)00400-7. doi: 10.1016/j.vetpar.2013.07.026 [Epub ahead of print].
• [12]Harrus S, Perlman-Avrahami A, Mumcuoglu KY, Morick D, Eyal O, Baneth G. 2011. Molecular detection of Ehrlichia canis, Anaplasma bovis, Anaplasma platys, Candidatus midichloria mitochondrii and Babesia canis vogeli in ticks from Israel. Clinical Microbiology and Infection, 17(3), 459–463.
• [13]Jongejan F, Uilenberg G. 2004. The global importance of ticks. Parasitology, 129(Suppl.), 3–14. [PubMed]
• [14]Jongejan F, Fourie JJ, Chester ST, Manavella C, Mallouk Y, Pollmeier MG, Baggott D. 2011. The prevention of transmission of Babesia canis canis by Dermacentor reticulatus ticks to dogs using a novel combination of fipronil, amitraz and (S)-methoprene. Veterinary Parasitology, 179, 343–350. [PubMed]
• [15]Otranto D, Paradies P, Testini G, Latrofa MS, Weigl S, Cantacessi C, Mencke N, de Caprariis D, Parisi A, Capelli G, Stanneck D. 2008. Application of 10% imidacloprid/50% permethrin to prevent Ehrlichia canis exposure in dogs under natural conditions. Veterinary Parasitology, 153, 320–328. [PubMed]
• [16]Satta G, Chisu V, Cabras P, Fois F, Masala G. 2011. Pathogens and symbionts in ticks: a survey on tick species distribution and presence of tick-transmitted micro-organisms in Sardinia, Italy. Journal of Medical Microbiology, 60(1), 63–68. [PubMed]
• [17]Shaw SE, Day MJ, Birtles RJ, Breitschwerdt EB. 2001. Tick-borne diseases of dogs. Trends in Parasitology, 17, 74–80. [PubMed]